Really do think I'm

Honestly can not find an issue with that line of thinking & i think it was you who said Dr. J is surely talking about the trial in a way that means --- ICI dose when/as needed

But I think for Briefing Book clarity --- they stuck to both CRC trials not including ICI

Which also does not "pressure" the FDA up-front. Let them be the decision maker & if so, that's fine because LL is the Stand Alone or Prime n Pair

The metastatic trial is choice ---- if had needed to choose

But....letting the FDA choose is similar to choosing to go Team-up with ICI's, instead of challenging them like 13D wanted to do.

ICI industry will consolidate itself anyway --- so why cause any problems

Same with this CRC/ICI --- no need to cause an appearence to the FDA of us trying to rush them into ICI before having presented..

Especially when they too, know what a No means & we have many more fish to fry, being --- a Metastatic trial

So yea, if, if im right ( sure feels like it all fits ) --- then it was a logical, good business risk. Yes sir.....